

RESEARCH PROJECTS

Katz G: A five-year, multi-center, commercial label safety study of TRAVATAN[®] 0.0004% in subjects with TRAVATAN[®] induced iris pigmentation changes. ALCON.

Katz G: A randomized, five-year post marketing safety study of xalatan compared to "usual care" in patients with open-angle glaucoma or ocular hypertension.

Katz G: A multi-center, double-masked, study of the safety and efficacy of TRAVATAN BAC-free compared to TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

Hassan TS: Complications of AMD prevention trial (CAPT) National Eye Institute, National Institutes of Health.

Hassan TS: Natural history study of patients with basal laminar drusen.

Hassan TS: A phase III clinical trial. Protein kinase C beta inhibitor-diabetic retinopathy study (PKC-DRS-2).

Hassan TS: A phase II/III randomized, double-masked, controlled, dose-ranging, multi-center comparative trial, in parallel groups, to establish the safety and efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every six weeks for 54 weeks. Eyetech Pharmaceuticals.

Hassan TS: A multi-center, randomized, masked, controlled study to evaluate retisert, an intravitreal fluocinolone acetonide implant, in the treatment of patients with diabetic macular edema. Bausch & Lomb.

Hassan TS: A phase II randomized, controlled, double-masked, dose-finding, multi-center, comparative trial, in parallel groups to establish the safety and preliminary efficacy of intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every six weeks for 12 to 30 weeks to patients with clinically significant diabetic macular edema involving the center of the macula. Eyetech Pharmaceuticals.

Hassan TS: An evaluation of efficacy and safety of posterior juxtasclear injection of anecortave acetate 15mg versus visudyne in patients with subfoveal exudative age-related macular degeneration (AMD) eligible for initial treatment with photodynamic therapy (PDT) using visudyne.

Hassan TS: Phase I/II, single-masked, multi-center study of the safety, tolerability, and activity of multiple dose intravitreal injections of rhuFabV2 in combination with verteporfin photodynamic therapy (visudyne) in subjects with neovascular age-related macular edema.

Hassan TS: Data and safety monitor. Intravitreal steroid injection studies (ISIS) trial.

Hassan TS: An open label, multi-center trial of the safety, tolerability and pharmacokinetics of 3 mg/eye intravitreal injections of EYE001 (Anti-VEGF Pegylated Aptamer) given every six weeks for 54 weeks in patients with exudative age-related macular degeneration. Eyetech Pharmaceuticals.

Hassan TS: An open label, multi-center trial of the safety, tolerability, and pharmacokinetics of 3mg/eye intravitreal injections of Eye001 (Anti-VEGF Pegylated Aptamer) given every six weeks for 54 weeks, in patients with exudative age-related macular degeneration. Eyetech Pharmaceuticals.

RESEARCH PROJECTS (CONT.)

Hassan TS: A prospective, multi-center clinical trial of the implantable miniature telescope (IMP) in patients with central vision impairment associated with age-related macular degeneration and stargardt's macular dystrophy.

Hassan TS: A phase I/II, single masked, multi-center study of the safety, tolerability, and activity of multiple dose intravitreal injections of rhuFab V2 in combination with verteporfin photodynamic therapy (visudyne) in subjects with neovascular age-related macular edema.

Hassan TS: A phase III, multi-center, randomized, double-masked, sham injection-controlled study of the efficacy and safety of rhuFab V2 (ranibizumab) in subjects with minimally classic or occult subfoveal neovascular age-related macular degeneration.

Hassan TS: A phase III, multi-center, randomized, double-masked, active treatment-controlled study of the efficacy and safety of rhuFab VS (ranibizumab) compared with verteporfin (visudyne) photodynamic therapy in subjects with predominantly classic subfoveal neovascular age-related macular degeneration.

Hassan TS: A safety and efficacy assessment of chimeric ribozyme to PCNA to prevent recurrence of proliferative vitreoretinopathy. Immusol Inc.

Hassan TS: Autologous plasmin enzyme (APE) to facilitate posterior vitreous detachment (PVD): A pilot study of NuVue Technologies' plasmin affinity cartridge kit. NuVue Technologies.

Hassan TS: Genetic and epidemiological study of age-related macular degeneration using sibpairs Massachusetts Eye and Ear Infirmary.

Hassan TS: A phase II randomized, double-masked, multi-center trial, in parallel groups, to determine the safety, efficacy, and pharmacokinetics of intravitreal injections of pegaptanib sodium compared to sham injection for 30 weeks in patients with recent vision loss due to macular edema secondary to CRVO. Eyetech Pharmaceuticals.

Hassan TS: An evaluation of efficacy and safety of posterior juxtasclear administrations of anecortave acetate for depot suspension (15mg or 30mg) versus sham administration in patients (enrolled in study "A" or study "B") at risk for developing sight-threatening choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD). Alcon Laboratories.

Hassan TS: A phase II randomized, masked, placebo-controlled, single and multiple-dose, sequential dose-escalation study of the safety and efficacy of AG-013958 in subjects with subfoveal choroidal neovascularization associated with age-related macular degeneration. Pfizer Inc.

ARTICLES APPEARING IN SCIENTIFIC JOURNALS

Hassan TS. The complications of age-related macular degeneration prevention trial (CAPT): Rationale, design, and methodology. *Clinical Trials* 2004;1:91-107.

Hassan TS. Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study. *Arch Ophthalmol* 2004;122:716-726.

Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. *Arch Ophthalmol* March 2004;122(3):317-321.

ARTICLES APPEARING IN SCIENTIFIC JOURNALS (CONT.)

Elliott D, Rezai KA, Dass AB, Lewis J. Management of retinal detachment in osteogenesis imperfecta. Arch Ophthalmol. 2003 Jul;121(7):1062-4.

Hassan TS. Potential public health impact of age-related eye disease study results. Arch Ophthalmol 2003; 121:1621-1624.

Probst LE, Holladay JT. Corneal refractive power after myopic LASIK. Ophthalmology. 2003 Sep;110(9):1857; author reply 1857-8.

ABSTRACTS, PRELIMINARY COMMUNICATIONS, PANEL DISCUSSIONS AND SCIENTIFIC MEETINGS (CONT.)

Greenbaum SM, Recchia FM, Cavalho-Recchia C, Hassan TS. Vision loss following photodynamic therapy for age-related macular degeneration. Poster presentation at the Association for Research in Vision Ophthalmology Annual Meeting, Fort Lauderdale, FL, May 4-9, 2003.

Recchia FM, Carvalho-Recchia CA, Hassan TS, Williams GA. Results of scleral buckling for repair of retinal detachments considered optimal for pneumatic retinopexy. Poster presentation at the American Academy of Ophthalmology Annual Meeting, Anaheim, CA, November 15-18, 2003.

Ruby AJ, Shaikh SA, Hassan TS. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Poster presentation at the American Academy of Ophthalmology Annual Meeting, Anaheim, CA, November 15-18, 2003.